James C. Shehan, Chair of Lowenstein’s FDA Regulatory practice, explains some lessons that general counsel should learn from the Theranos case in Corporate Counsel. Shehan advises in-house lawyers to look out for certain red flags, such as poor communication or lack of industry expertise in company leadership. He says, “[W]ithout appropriate expertise, bringing any product or service to market could prove an insurmountable obstacle for even the most ambitious start-up.” Shehan further cautions general counsel to “look out for potential conflicts of interest when executives wear multiple hats, as is common at start-ups.” Finally, he says, “[S]ometimes the situation is so bad that you have no choice but to resign.”